Editorial Zambrano & Salazar In the field of statin therapy, huge efforts on a genome-wide scale have been performed to elucidate the genetic determinants of statin response [4] [5] [6] . Despite being necessary, the results have not been accompanied with the corresponding clinical success, confirming the role of a few previously associated genes and revealing an even smaller number of novel and potentially significant loci associated with statin interindividual or intraindividual differential response. Despite advancing the personalized medicine field, statin research is just not there yet, as the evidence from these large meta-analyses only contribute a residual overall explanation to statin response variability, generating at least two clear conclusions: the results from these studies still cannot be translated as they do not exceed a minimal threshold to be incorporated into the clinical decision-making process, which already is a matter of intense debate [7] and additional mechanisms may be involved. Nonetheless, obstacles found and foreseen in the translation of pharmacogenomic knowledge to bedside led to the creation of the Clinical Pharmacogenetics Implementation Consortium (CPIC) [8] , a nonprofit international organization aimed at developing standardized guidelines on the use of genomic data, pushing forward the incipient arrival of precision medicine to clinical care.
Remarkably, the pioneer investigations performed by the Nobel Laureates in Physiology or Medicine, Michael S Brown and Joseph L Goldstein, disclosing the LDLR pathway of cholesterol metabolism [9] are still tremendously valid, even though they were reported more than three decades ago. With solid precision, the advance of science boundaries makes it possible to fuse the new lessons obtained from miRNA research with the old lessons taught from the LDLR pathway in an effort to offer another explanation to fill the current gap regarding response variability of statin treatment. Why? As widespread as they can be, miRNAs not only play a role, but are essential for the regulation of crucial genes implicated in the molecular pathway formerly described by Brown and Goldstein, which has been clearly demonstrated using both in vitro and in vivo models [10, 11] . But do statins take part in the interplay between miRNAs and their target genes? We and others have reported positive findings on this issue [12, 13] , suggesting that, for instance, miRNAs can be modulated in subjects with hypercholesterolemia, and that the modulation is dependent on the type of statin employed [14] , meaning that miRNAs are likely to be implicated in the differential response observed with different statin treatments.
At this point in time, the emerging field of miRNAs and statin research is experiencing a strong interest with exceptional results. Mutations of a previously unknown protein termed PCSK9 causing autosomal dominant hypercholesterolemia [15] revealed a new main character to be added to the well described LDLR pathway in cholesterol regulation. Moreover, subsequent studies on this seminal breakthrough revealed PCSK9 gain-of-function and loss-of-function variations associated with autosomal dominant hypercholesterolemia and low cholesterol levels, respectively. Thus, the protein function -to cleave LDLR -makes PCSK9 a possible target to be therapeutically manipulated. In fact, it has been recently demonstrated that a number of miRNAs control PCSK9 [16] , but a significant amount of accumulated knowledge makes the plot thicker. As above mentioned, statins are the preferred lipid-lowering drug to decrease LDL-C, but one of the reasons that statins may not be fully capable to reduce cholesterol levels with a superior efficiency is that, besides increasing LDLR to remove LDL-C from circulation, statins also increase PCSK9-related lysosomal LDLR degradation, which could be especially important when using medium to high intensity statin doses [17] . Yet, a 2015 report concluded that both LDLR and PCSK9 pathways could be therapeutically manipulated by inhibiting miRNA-27a, an miRNA that normally decreases LDLR while increasing both mRNA and secreted PCSK9 [18] . Hence, various studies support the feasibility of considering miRNAs as therapeutic targets for FH, a scenario that has already reached clinical impact [19] . Consequently, the use of miRNAs as PCSK9 inhibitors is considered nowadays a practical therapeutic approach [20] , having in mind the recent US FDA approval of Evolocumab and Alirocumab, two novel medications for LDL-C reduction based on PCSK9 inhibition.
Finally, is the massive task of making precision medicine a reality completely within our reach? To know what we do not know, a large road remains ahead, as a growing number of continuous breakthroughs demonstrate us that accumulated knowledge so far can only expand, especially in the postgenomic era. However, and without a doubt, the most enlightening path is to continue research, accelerating its translation into clinical practice.
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